AI Article Synopsis

  • Malignant struma ovarii (MSO) is an uncommon ovarian tumor mainly made up of thyroid tissue, often spreading to areas like the peritoneum, bones, and lungs.
  • A case study involves a woman in her 50s who had a history of ovary removal and presented with a pituitary mass, which was mistakenly thought to be a pituitary tumor but turned out to be metastatic thyroid tissue from MSO.
  • After surgery and treatment with radioactive iodine, the patient showed a positive response, with no signs of tumor recurrence or new metastases after five years of monitoring.

Article Abstract

Malignant struma ovarii (MSO) is a rare ovarian teratoma composed primarily of thyroid tissue. Common sites of metastasis include peritoneum, bone, liver, lung, gastrointestinal tract and omentum. We present a woman in her 50s with a history of remote oophorectomy presenting with hypopituitarism and a 2.7 cm sellar mass. Trans-sphenoidal surgery for presumed pituitary macroadenoma achieved near total resection and resultant pathology surprisingly showed ectopic thyroid tissue. The patient acquired her ovarian pathology report from Southeast Asia which showed struma ovarii of the left ovary. The pituitary mass was thus determined to be a metastatic lesion from MSO. She underwent total thyroidectomy and radioactive iodine ablation therapy with good initial response and no regrowth of the tissue or emergence of distant metastases after 5 years of annual follow-up. To our knowledge, this is the first reported case of MSO to the pituitary.

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2023-259391DOI Listing

Publication Analysis

Top Keywords

struma ovarii
12
malignant struma
8
sellar mass
8
total thyroidectomy
8
radioactive iodine
8
thyroid tissue
8
metastatic malignant
4
pituitary
4
ovarii pituitary
4
pituitary presenting
4

Similar Publications

Diagnostic Value of Nuclear Hybrid Imaging in Malignant Struma Ovarii: A Systematic Review of Case Reports.

Diagnostics (Basel)

November 2024

Faculty of Medicine, Department of Medical Imaging and Nuclear Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8 V. Babeș St., 400006 Cluj-Napoca, Romania.

Background: Struma ovarii is a rare tumor, a type of ovarian mature teratoma consisting over 50% of its mass in thyroid ectopic tissue; 5% to 10% of cases, as described in the literature, are malignant and well known as malignant struma ovarii or thyroid cancer from struma ovarii. Due to the limited number of malignant struma ovarii cases, the diagnostic and therapeutic approach of malignant struma ovarii lacks in standardization.

Methods: We performed a comprehensive search on the English language PubMed and Google Scholar.

View Article and Find Full Text PDF

Presentation and Management of Highly Differentiated Follicular Carcinoma of Ovarian Origin With Gene Variants.

JCEM Case Rep

December 2024

Division of Endocrinology, Gerontology, and Metabolism, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.

Struma ovarii (SO) is a rare subtype of ovarian teratoma composed of more than 50% thyroid tissue. Extraovarian spread of SO, called peritoneal strumosis, was previously considered benign given the lack of histological malignant features. However, the 2020 World Health Organization Classification of Female Genital Tumors reclassified peritoneal strumosis as highly differentiated follicular carcinoma of ovarian origin (HDFCO), highlighting its low-grade malignant potential.

View Article and Find Full Text PDF

Disease management of malignant struma ovarii.

Hell J Nucl Med

December 2024

Department of Nuclear Medicine, Qiantang Branch of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Article Synopsis
  • - Malignant struma ovarii (MSO) is a rare type of ovarian goiter that meets criteria for malignant thyroid tumors and can show invasive spread, with serum thyroglobulin (Tg) levels helping to differentiate it from other ovarian cancers.
  • - A case study is presented involving a 54-year-old woman with abdominal pain, diagnosed post-surgery with highly differentiated follicular thyroid carcinoma originating from both ovaries, which had spread to other areas.
  • - After undergoing total thyroidectomy and iodine-131 treatment, her follow-up after one year showed no significant abnormalities, highlighting the need for further discussion on clinical management and monitoring of Tg levels in MSO cases.
View Article and Find Full Text PDF

Malignant struma ovarii in pregnancy: A case report.

Gynecol Oncol Rep

December 2024

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, McMaster University, 699 Concession Street, Hamilton, Ontario L8V 5C2, Canada.

Article Synopsis
  • * A 27-year-old pregnant patient was diagnosed with malignant struma ovarii after emergency surgery for ovarian torsion revealed a 3 cm tumor, initially monitored during pregnancy due to the lack of high-risk features.
  • * After giving birth, the patient had a recurrence treated with extensive surgeries and radioactive iodine therapy, and she remained disease-free three years post-diagnosis, highlighting the need for personalized treatment approaches for MSO.
View Article and Find Full Text PDF
Article Synopsis
  • The study aims to evaluate long-term survival rates and the effects of thyroid-related treatments in patients with malignant struma ovarii (MSO) after surgical treatment.
  • A systematic review was conducted, analyzing 376 patients from both case reports and case series, with a primary focus on overall survival (OS) outcomes using statistical methods.
  • Results indicated a high OS rate (91% at 10 years, 87% at 20 years) regardless of the type of thyroid-related therapy received, suggesting these treatments may not significantly improve survival and could be considered excessive.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!